Zhejiang Jiuzhou Pharm Co Ltd
Zhejiang Jiuzhou Pharmaceutical Co., Ltd operates as contract development and manufacturing organization (CDMO) company in China and internationally. The company offers small molecule, drug product, and peptide CDMO services. It also involved in business related to supporting the development of new drugs and pharmaceuticals. It serves global pharmaceutical companies, biotechnology companies, and … Read more
Zhejiang Jiuzhou Pharm Co Ltd (603456) - Total Assets
Latest total assets as of June 2025: CN¥10.96 Billion CNY
Based on the latest financial reports, Zhejiang Jiuzhou Pharm Co Ltd (603456) holds total assets worth CN¥10.96 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zhejiang Jiuzhou Pharm Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Zhejiang Jiuzhou Pharm Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Zhejiang Jiuzhou Pharm Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhejiang Jiuzhou Pharm Co Ltd's total assets of CN¥10.96 Billion consist of 54.6% current assets and 45.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 24.7% |
| Accounts Receivable | CN¥1.20 Billion | 10.7% |
| Inventory | CN¥1.93 Billion | 17.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥572.93 Million | 5.2% |
| Goodwill | CN¥88.60 Million | 0.8% |
Asset Composition Trend (2011–2024)
This chart illustrates how Zhejiang Jiuzhou Pharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Jiuzhou Pharm Co Ltd's current assets represent 54.6% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 24.7% of total assets in 2024, up from 8.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 6.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 17.3% of total assets.
Zhejiang Jiuzhou Pharm Co Ltd Competitors by Total Assets
Key competitors of Zhejiang Jiuzhou Pharm Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Zhejiang Jiuzhou Pharm Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Zhejiang Jiuzhou Pharm Co Ltd generates 0.46x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Zhejiang Jiuzhou Pharm Co Ltd generates $5.45 in net profit.
Zhejiang Jiuzhou Pharm Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.05 | 3.31 | 1.61 |
| Quick Ratio | 2.21 | 2.36 | 0.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.91 Billion | CN¥ 4.45 Billion | CN¥ 843.15 Million |
Zhejiang Jiuzhou Pharm Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhejiang Jiuzhou Pharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.92 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | 2.5% |
| Total Assets | CN¥11.13 Billion |
| Market Capitalization | $1.12 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Jiuzhou Pharm Co Ltd's assets below their book value (0.10 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Zhejiang Jiuzhou Pharm Co Ltd's assets grew by 2.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Zhejiang Jiuzhou Pharm Co Ltd (2011–2024)
The table below shows the annual total assets of Zhejiang Jiuzhou Pharm Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥11.13 Billion | +2.54% |
| 2023-12-31 | CN¥10.85 Billion | +37.14% |
| 2022-12-31 | CN¥7.91 Billion | +12.40% |
| 2021-12-31 | CN¥7.04 Billion | +40.76% |
| 2020-12-31 | CN¥5.00 Billion | +7.10% |
| 2019-12-31 | CN¥4.67 Billion | +41.31% |
| 2018-12-31 | CN¥3.30 Billion | +5.17% |
| 2017-12-31 | CN¥3.14 Billion | +4.79% |
| 2016-12-31 | CN¥3.00 Billion | -10.09% |
| 2015-12-31 | CN¥3.34 Billion | +51.04% |
| 2014-12-31 | CN¥2.21 Billion | +42.37% |
| 2013-12-31 | CN¥1.55 Billion | +15.46% |
| 2012-12-31 | CN¥1.34 Billion | +20.63% |
| 2011-12-31 | CN¥1.11 Billion | -- |